KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals
Funding positions KROMATID for accelerated growth in genomic analysis and gene editing technologies BOULDER, Colo., Aug. 20, 2025 /PRNewswire/ — KROMATID, a leader in next-generation genomic structural analysis, today announced the successful close of its Series C…
